Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Up 4.4%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) shot up 4.4% during trading on Wednesday . The company traded as high as $14.16 and last traded at $14.09. 60,327 shares were traded during mid-day trading, a decline of 81% from the average session volume of 317,124 shares. The stock had previously closed at $13.50.

Analyst Ratings Changes

CNTA has been the topic of a number of recent research reports. Morgan Stanley boosted their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th.

Centessa Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. The firm’s 50-day moving average price is $11.01 and its two-hundred day moving average price is $10.32. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -10.28 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, analysts expect that Centessa Pharmaceuticals plc will post -1.61 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the transaction, the insider now owns 241,171 shares of the company’s stock, valued at $2,935,051.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Saurabh Saha sold 4,169 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at approximately $10,197,941.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,873 shares of company stock worth $206,000. Insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $48,000. Sandia Investment Management LP purchased a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at $90,000. Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter worth about $99,000. EntryPoint Capital LLC purchased a new position in Centessa Pharmaceuticals during the 1st quarter valued at about $109,000. Finally, Trexquant Investment LP acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.